T he annual meeting of the American Society of Clinical Oncology is the most visible showcase for new cancer drug data. Join ...

Deputy directors at the FDA center that oversees the regulation of cancer drugs plan to leave, adding to a flood of top ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response ...

CG Oncology, Inc. ( ($CGON) ) has released its Q4 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.

As more people receive genetic testing after a cancer diagnosis, newer variants have been identified that increase the risk ...

What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...